Introduction

39
The advent of highly active antiretroviral therapy (HAART) for HIV infection represents a major 40 accomplishment of modern medicine. Despite this, however, the occurrence of drug resistance which confer resistance while reducing viral fitness, are followed by compensatory substitutions 57 that restore fitness while further increasing levels of resistance. The INSTIs raltegravir (RAL) 58 and elvitegravir (EVG) are compromised by substitutions at positions Y143, Q148 and N155 (8, 59 9), and additionally at position E92 for EVG alone (10). In contrast, resistance to the newer 60 INSTI dolutegravir (DTG) is associated with a substitution at position R263K, and no 61 compensatory substitution for R263K has yet been identified (11). The lack of such 62 compensation may help to explain the absence of detectable emerging resistance substitutions in 63 treatment-naïve individuals failing DTG-based therapy (11) (12) (13) (14) . 
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The G118R substitution was reported to emerge during selection studies with DTG as well as 65 with the experimental integrase inhibitor MK-2048 (15, 16) glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin and kept at 37°C under 5% CO 2 .
96
Umbilical cord blood mononuclear cells (CBMCs) were isolated by Ficoll-Hypaque (GE The stHIV-1 (SCA, SVIF) plasmid was constructed (5) and kindly provided by Dr. Theodora The production of genetically homogeneous stHIV-1 wild-type (WT) or mutated viruses was Non-competitive short-term infectivity assays with TZM-bl cells (n=6) were used to determine 143 the infectivity of the stHIV-1 wild-type and mutant viruses as previously described for HIV-1 Long-term infection assays were used to quantify stHIV-1 replication capacity in rhesus 
Results
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Effect of integrase substitutions on stHIV-1(SCA,SVIF) infectivity
Single-cycle infection assays with TZM-bl cells were used to determine the infectivity of stHIV- 
Susceptibility of stHIV-1 mutant viruses to INSTIs
217
Previous studies with HIV revealed that the insertion of DRMs into the integrase region of N155H, and Y143R displaying increases in EC 50 of 11.5-, 14.7-, and 35.9-fold, respectively, 223 compared to WT (Table 1) . Viruses containing G118R conferred low-level resistance to RAL
224
(5.8-fold), whereas the E138K, R263K, and S153Y viruses did not significantly confer resistance 225 to this drug (0.41-, 0.83-, and 1.59-fold, respectively). All mutated stHIV-1 viruses conferred 226 moderate-to-high levels of resistance to EVG, ranging from 16.6-fold for E138K to > 300-fold 227 for E92Q. With respect to DTG, the mutated viruses were associated with low levels of resistance, with viruses containing G118R conferring the highest level of resistance (6.4-fold) .
229
The R263K substitution did not confer significant levels of resistance against RAL, but did 230 confer low-and moderate-level resistance to DTG (2.5-fold) and EVG (32.6-fold), respectively. systems.
241
Our results show that stHIV-1 and HIV-1 share similar resistance pathway profiles (Table 1) . As 242 an example, the E92Q substitution, which has been shown to be prevalent in patients failing
243
EVG-based therapy (23-28), was associated with the highest level of resistance against this drug 244 when introduced into stHIV-1. In agreement with our studies on the role of the G118R 245 substitution in HIV-1 (29), this substitution was the only one that conferred moderate-level 246 resistance in stHIV-1 against DTG (FC=6.4-fold). This is in agreement with observations on the 247 robustness of this drug against most resistance substitutions (7, 30). Similarly, the R263K 248 substitution in integrase resulted in low-level resistance against DTG in stHIV-1 (Table 1) and HIV, i.e. fold-changes of 2.2 and 2.5-fold, respectively (Table 1) , whereas S153Y conferred 255 high-level resistance against EVG in stHIV-1 (22.8-fold) and low-level resistance against this R263K-containing HIV-1. In particular, the G118R and R263K DTG-specific substitutions were the most detrimental to stHIV-1 viral infectivity (Figure 1 ). S153Y was also associated with a 275 high degree of impairment of viral replication. RAL and EVG-specific DRMs, i.e. E92Q,
276
E138K, Y143R and N155H, were less detrimental to stHIV-1 replication capacity than were
277
R263K and G118R and N155H was the least disadvantageous for viral infectiousness.
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The HIV-based chimeric virus, stHIV-1, was derived by replacing the capsid and vif regions of 2.3**** 1**** 21.8**** From *Kobayashi, AAC, 2010; **Anstett, submitted for publication; ***Bar-Magen et al, JVI, 2010 and unpublished observations; ****Mesplède et al., JAC, 2014 
